Effects of task-oriented training combined with aerobic training on serum BDNF, GDNF, IGF-1, VEGF, TNF-α, and IL-1β levels in people with Parkinson's disease: A randomized controlled study

What Was Tested

This randomized controlled trial paper looks at IGF-1 LR3 in the context of parkinson's disease.

Thus, the aim of the present study was to investigate the effects of TOT combined with AT (TOT-AT) on serum brain-derived neurotrophic factor (BDNF), glial cell-derived growth factor (GDNF), insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels in people with PD (PwPD).

Why It Was Studied

However, molecular mechanisms which may underlie exercise-induced neuroprotection are still largely unknown.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.

Forty PwPD were randomized into 8-week of either exercise group (n = 20) or control group (n = 20).

The exercise group received TOT-AT while the control group received only AT.

Serum BDNF, GDNF, IGF-1, VEGF, TNF-α, and IL-1β levels determined with ELISA were assessed at baseline and after training.

What Was Measured

PubMed files the paper under topics including Brain-Derived Neurotrophic Factor, Glial Cell Line-Derived Neurotrophic Factor, Insulin-Like Growth Factor I, Interleukin-1beta, Neurodegenerative Diseases, Parkinson Disease and Tumor Necrosis Factor-alpha.

The authors tagged it with the keywords Exercise, Neurotrophic factors, Parkinson's disease and Proinflammatory cytokines.

What This Means in Plain Language

The paper is a randomized study of IGF-1 LR3 in people with parkinson's disease.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Experimental gerontology), a journal based in England.

More context: the IGF-1 LR3 compound page, Parkinson's disease research.